New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UKAbstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and l...
Saved in:
| Main Authors: | Gledhill T, Bodger K |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2013
|
| Subjects: | |
| Online Access: | https://doaj.org/article/df0a4f9f36d540c88a56d09b35666d56 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016) -
Infliximab in ulcerative colitis
by: Avi Levin, et al.
Published: (2008) -
Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
by: Jun Miyoshi, et al.
Published: (2021) -
Golimumab in unresponsive ulcerative colitis
by: Lippert E, et al.
Published: (2014) -
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
by: Bradley GM, et al.
Published: (2012)